Identifying new markers for breast cancer prognosis
Official title: Identification de Nouveaux Marqueurs Pronostiques Des Cancers du Sein
Run by University Hospital, Grenoble · NCT03436069 · Data updated 2026-11-12
This study is trying to find new genetic markers in breast cancer tumors to help predict how the disease will progress and improve treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 1500 (estimated) |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Status | Recruiting |
| Started | January 2011 |
| Main results expected | December 31, 2033 |
| Study ends | December 31, 2033 |
| Registry record updated | February 28, 2023 |
| Trial ID | NCT03436069 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult female patients diagnosed with breast cancer.
✕Probably not a fit
Patients with other active cancers or those unable to provide necessary information due to language barriers or recent relocation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify and validate new prognostic markers for breast cancer using tumor samples from both retrospective and prospective cohorts. The research leverages an innovative approach developed by the team, which focuses on detecting ectopic gene expression through public pan-genomic breast cancer data. By correlating these genetic markers with clinical outcomes, the study seeks to improve the assessment of relapse and metastasis risks, ultimately enhancing treatment personalization and minimizing side effects for patients.
Why it matters
Potential benefit: If successful, this study could lead to more accurate prognostic assessments for breast cancer patients, allowing for tailored treatment strategies.
How similar studies have gone: Previous studies have successfully utilized similar approaches in other cancers, indicating potential for success in this context as well.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult female patients with breast cancer Exclusion Criteria: * Presence of another cancer, excluding basal cell cancers or pre-neoplastic lesions of the cervix. * Subject under guardianship or subject deprived of liberty * Impossibility of collecting information on exposure (subjects recently arrived in France, foreign language, etc.) * Male patients
Where it's running
-
Anne-Cécile PHILIPPE
Grenoble, France Recruiting
Study contacts
- Principal investigator: Anne-Cécile PHILIPPE, Dr — University Hospital, Grenoble
- Study coordinator: Anne-Cécile PHILIPPE, Dr
- Email: ACPhilippe@chu-grenoble.fr
- Phone: +33476766677
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.